|
1
|
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.
|
J Exp Med
|
2008
|
1.34
|
|
2
|
Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts.
|
Am J Pathol
|
2010
|
1.21
|
|
3
|
Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.
|
J Immunol
|
2009
|
1.15
|
|
4
|
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.
|
Blood
|
2007
|
1.09
|
|
5
|
Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity.
|
J Biol Chem
|
2010
|
0.98
|
|
6
|
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.
|
Arthritis Res Ther
|
2006
|
0.96
|
|
7
|
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells.
|
Arterioscler Thromb Vasc Biol
|
2012
|
0.91
|
|
8
|
Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
|
Biochem Pharmacol
|
2004
|
0.78
|